Merrimack Pharmaceuticals Inc (MACK):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Merrimack Pharmaceuticals Inc (MACK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9789
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Merrimack Pharmaceuticals Inc (Merrimack) is a clinical stage biopharmaceutical company that develops and commercializes medicines for the treatment of various types of cancers. The company’s marketed portfolio consists of Onivyde (irinotecan liposome injection) that encases irinotecan (marketed chemotherapy drug) in a liposomal formulation used in the treatment of pancreatic metastatic adenocarcinoma. Its pipeline portfolio includes investigational candidates targeted at the treatment of advanced non-small cell lung cancer (NSCLC), solid tumors, metastatic breast cancer, and heregulin positive breast cancer. The company sells its products through a network of distributors in the US. Merrimack is headquartered in Cambridge, Massachusetts, the US.

Merrimack Pharmaceuticals Inc (MACK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Merrimack Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Merrimack Pharma Amends Co-Development Agreement With Actavis 12
Merrimack Pharma Enters Into Co-Development Agreement With Cancer Treatment Centers of America 13
Licensing Agreements 14
Merrimack Pharma Enters into Licensing Agreement with Ipsen 14
Baxter International Enters into Licensing Agreement with Merrimack Pharma for MM-398 15
Merrimack Pharma Amends Licensing Agreement with PharmaEngine for MM-398 17
Equity Offering 19
Merrimack Pharma Plans to Raise up to USD40 Million in Public Offering of Shares 19
Merrimack Pharma Completes Public Offering Of Shares For US$28.8 Million 20
Merrimack Pharma Completes IPO For US$100 Million 22
Debt Offering 24
Merrimack Pharma Raises USD175 Million in Private Placement of 11.5% Notes Due 2022 24
Merrimack Pharma Completes Public Offering Of Notes Due 2020 For US$125 Million 25
Asset Transactions 27
Ipsen Acquires Oncology Assets from Merrimack Pharma 27
Merrimack Pharmaceuticals Inc – Key Competitors 29
Merrimack Pharmaceuticals Inc – Key Employees 30
Merrimack Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 07, 2018: Merrimack reports third quarter 2018 financial results and provides strategic update following portfolio review 32
Aug 07, 2018: Merrimack reports second quarter 2018 financial results 34
May 08, 2018: Merrimack Reports First Quarter 2018 Financial Results 36
Mar 12, 2018: Merrimack Reports 2017 Financial Results 37
Nov 08, 2017: Merrimack Reports Third Quarter 2017 Financial Results 39
Aug 09, 2017: Merrimack Reports Second Quarter 2017 Financial Results 40
May 10, 2017: Merrimack Reports First Quarter 2017 Financial Results 41
Mar 01, 2017: Merrimack Reports Fourth Quarter and Full-Year 2016 Financial Results 43
Corporate Communications 45
Feb 20, 2018: Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology 45
Nov 30, 2017: Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors 46
Aug 14, 2017: Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer 47
Jun 08, 2017: Merrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chief Medical Officer and Ellen Forest as Head of Human Resources 48
May 25, 2017: Merrimack Announces Management Change 49
Jan 18, 2017: Merrimack Names Richard Peters, M.D., Ph.D., as President and CEO 50
Clinical Trials 51
Jun 19, 2017: Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018 51
Mar 27, 2017: Merrimack to Present Data on Istiratumab (MM-141) at the 2017 American Association for Cancer Research Annual Meeting 52
Mar 27, 2017: Merrimack to Present Data on MM-151 at the 2017 American Association for Cancer Research Annual Meeting 53
Mar 27, 2017: Merrimack to Present Data on MM-161 at the 2017 American Association for Cancer Research Annual Meeting 54
Mar 27, 2017: Merrimack to Present Data on MM-310 at the 2017 American Association for Cancer Research Annual Meeting 55
Mar 23, 2017: Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Merrimack Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Merrimack Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Merrimack Pharma Amends Co-Development Agreement With Actavis 12
Merrimack Pharma Enters Into Co-Development Agreement With Cancer Treatment Centers of America 13
Merrimack Pharma Enters into Licensing Agreement with Ipsen 14
Baxter International Enters into Licensing Agreement with Merrimack Pharma for MM-398 15
Merrimack Pharma Amends Licensing Agreement with PharmaEngine for MM-398 17
Merrimack Pharma Plans to Raise up to USD40 Million in Public Offering of Shares 19
Merrimack Pharma Completes Public Offering Of Shares For US$28.8 Million 20
Merrimack Pharma Completes IPO For US$100 Million 22
Merrimack Pharma Raises USD175 Million in Private Placement of 11.5% Notes Due 2022 24
Merrimack Pharma Completes Public Offering Of Notes Due 2020 For US$125 Million 25
Ipsen Acquires Oncology Assets from Merrimack Pharma 27
Merrimack Pharmaceuticals Inc, Key Competitors 29
Merrimack Pharmaceuticals Inc, Key Employees 30
Merrimack Pharmaceuticals Inc, Subsidiaries 31

List of Figures
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Merrimack Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Merrimack Pharmaceuticals Inc (MACK):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HRG Group, Inc. (HRG):企業の財務・戦略的SWOT分析
    HRG Group, Inc. (HRG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Sectra AB (SECT B):企業の財務・戦略的SWOT分析
    Sectra AB (SECT B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Deutsche Borse AG:企業の戦略・SWOT・財務情報
    Deutsche Borse AG - Strategy, SWOT and Corporate Finance Report Summary Deutsche Borse AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Blue Cross and Blue Shield Association:企業の戦略的SWOT分析
    Blue Cross and Blue Shield Association - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • AirStrip Technologies Inc-医療機器分野:企業M&A・提携分析
    Summary AirStrip Technologies Inc (AirStrip) is a healthcare solution provider that offers medical software solutions and services. The company offers mobile interoperability platform, accelerator services and wireless maternal-fetal monitoring solutions. It caters its products to healthcare provide …
  • Berjaya Corporation Berhad:企業の戦略・SWOT・財務分析
    Berjaya Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary Berjaya Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Sykes Enterprises, Incorporated:企業の戦略・SWOT・財務分析
    Sykes Enterprises, Incorporated - Strategy, SWOT and Corporate Finance Report Summary Sykes Enterprises, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • CohBar Inc (COB.U):企業の財務・戦略的SWOT分析
    Summary CohBar Inc (CohBar) is a developer of mitochondria based therapeutics. The company develops a class of drugs to treat a wide range of diseases associated with aging and metabolic dysfunction such as non-alcoholic steatohepatitis, obesity, type 2 diabetes, cancer, cardiovascular disease and C …
  • Guernsey Electricity Ltd:企業の戦略的SWOT分析
    Guernsey Electricity Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Matrix Service Co:企業の戦略・SWOT・財務分析
    Matrix Service Co - Strategy, SWOT and Corporate Finance Report Summary Matrix Service Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Seagate Technology Public Limited Company:企業のM&A・事業提携・投資動向
    Seagate Technology Public Limited Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Seagate Technology Public Limited Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detaile …
  • Midea Group Co Ltd
    Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Northwest Pipe Co (NWPX):企業の財務・戦略的SWOT分析
    Northwest Pipe Co (NWPX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Firstec Co., Ltd.:企業の戦略・SWOT・財務分析
    Firstec Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Firstec Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • EnGeneIC Ltd-製薬・医療分野:企業M&A・提携分析
    Summary EnGeneIC Ltd (EnGeneIC) is a biopharmaceutical company that develops drugs and other therapeutic molecules. The company develops nanocell platform used as a platform for the creation of custom therapies for cancer. Its cyto-immunotherapy platform releases concentrations of RNA-interference m …
  • L-3 Unmanned Systems, Inc.:企業の戦略・SWOT・財務分析
    L-3 Unmanned Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary L-3 Unmanned Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • SmartCool Systems Inc (SSC):企業の財務・戦略的SWOT分析
    Summary SmartCool Systems Inc (SmartCool Systems) is a clean technology company that manufactures and sells energy and cost reduction technologies. The company’s products include ECO3, ESM, and soft solutions. Its ECO3 and ESM are retrofit technologies that reduce the energy consumption of compresso …
  • Dr. Reddy’s Research and Development BV-医療機器分野:企業M&A・提携分析
    Summary Dr. Reddy’s Research and Development BV (Dr. Reddy’s Research and Development), a subsidiary of Dr. Reddy's Laboratories Ltd is a drug formulation and manufacturing service provider that develops and manufactures improved injectable pharmaceuticals. The company offers services such as formul …
  • Myovant Sciences Ltd (MYOV):製薬・医療:M&Aディール及び事業提携情報
    Summary Myovant Sciences Ltd (Myovant), a subsidiary of Roivant Sciences Ltd, is a biopharmaceutical company that develops and commercializes new treatments for women’s diseases and endocrine disorders. The company’s products include relugolix, an oral small molecule that functions as a gonadotropin …
  • Continuus Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Continuus Pharmaceuticals Inc (Continuus) is a provider of integrated continuous manufacturing technology for small molecule pharmaceuticals. The company offers an integrated continuous manufacturing technology that produces finished drug tablets from raw chemical ingredients without interru …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆